Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) EBIT Margin (2016 - 2020)

Historic EBIT Margin for KalVista Pharmaceuticals (KALV) over the last 7 years, with Q2 2020 value amounting to 234.23%.

  • KalVista Pharmaceuticals' EBIT Margin rose 1505900.0% to 234.23% in Q2 2020 from the same period last year, while for Apr 2020 it was 319.42%, marking a year-over-year decrease of 1344900.0%. This contributed to the annual value of 3249.7% for FY2025, which is 35305900.0% up from last year.
  • As of Q2 2020, KalVista Pharmaceuticals' EBIT Margin stood at 234.23%, which was up 1505900.0% from 806.85% recorded in Q1 2020.
  • Over the past 5 years, KalVista Pharmaceuticals' EBIT Margin peaked at 61.34% during Q2 2018, and registered a low of 93257.14% during Q1 2016.
  • Over the past 5 years, KalVista Pharmaceuticals' median EBIT Margin value was 384.83% (recorded in 2019), while the average stood at 6612.27%.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' EBIT Margin tumbled by -232428600bps in 2016, and later soared by 54916900bps in 2018.
  • KalVista Pharmaceuticals' EBIT Margin (Quarter) stood at 2043.15% in 2016, then surged by 74bps to 526.8% in 2017, then surged by 83bps to 87.5% in 2018, then crashed by -171bps to 236.96% in 2019, then grew by 1bps to 234.23% in 2020.
  • Its last three reported values are 234.23% in Q2 2020, 806.85% for Q1 2020, and 236.96% during Q4 2019.